|
Shareholder Letter |
|
Structural and Biophysical Characterization of the Origins of the PPAR Selectivity of Seladelpar and Elafibranor, Peroxisomal Proliferator Activated Receptor (PPAR) Agonists Targeting Inflammatory Liver Diseases |
|
Pharmacokinetics of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) with or without Cirrhosis |
|
Seladelpar 12-Week Topline Data NASH Phase 2b Study |
|
Seladelpar for the Treatment of Primary Biliary Cholangitis, Experience with 25 Cirrhotic Patients |
